Literature DB >> 11145989

Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease.

A J Morton1, J M Edwardson.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by motor, emotional and cognitive dysfunction. There is no treatment or cure for this disease, and after the onset of symptoms, usually in the fourth decade of life, there is an inexorable decline to death. In many patients there is a complex deterioration of function before the onset of neuronal loss and, at least in mouse models, abnormalities in neurotransmission represent early events in the development of the disease. Here we describe the specific and progressive loss of complexin II from the brains of mice carrying the HD mutation (R6/2 line), and the later appearance of this protein in a subpopulation of neuronal intranuclear inclusions. Although the precise role of complexin II is still unclear, it is known to bind to the SNARE complex, and is therefore likely to be involved in the control of exocytosis. Our results suggest that changes in neurotransmitter release might contribute to the neuronal dysfunction seen in these mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145989     DOI: 10.1046/j.1471-4159.2001.00059.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

Review 1.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Amyloid-β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a.

Authors:  Yoosoo Yang; Jaewook Kim; Hye Yun Kim; Nayeon Ryoo; Sejin Lee; YoungSoo Kim; Hyewhon Rhim; Yeon-Kyun Shin
Journal:  Cell Rep       Date:  2015-08-13       Impact factor: 9.423

Review 3.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

4.  Kinetics of complexin binding to the SNARE complex: correcting single molecule FRET measurements for hidden events.

Authors:  Yulong Li; George J Augustine; Keith Weninger
Journal:  Biophys J       Date:  2007-05-18       Impact factor: 4.033

Review 5.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

6.  Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.

Authors:  Mark J Hunt; A Jennifer Morton
Journal:  Exp Brain Res       Date:  2005-07-21       Impact factor: 1.972

7.  Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.

Authors:  Ahmad Khedraki; Eric J Reed; Shannon H Romer; Qingbo Wang; William Romine; Mark M Rich; Robert J Talmadge; Andrew A Voss
Journal:  J Neurosci       Date:  2017-07-19       Impact factor: 6.167

8.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 9.  Transcriptional signatures in Huntington's disease.

Authors:  Jang-Ho J Cha
Journal:  Prog Neurobiol       Date:  2007-04-01       Impact factor: 11.685

10.  Maintenance of chaperone-mediated autophagy activity in cultured cells expressing mutant huntingtin.

Authors:  Xiang Li; Jianbin Wang
Journal:  Biomed Rep       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.